The positive readout from the CheckMate-76K study means that Opdivo (nivolumab) has a chance to draw level again with Merck & Co's rival cancer immunotherapy Keytruda (pembrolizumab), which was ...
Zacks.com on MSN6mon
Bristol Myers (BMY) Fails to Meet Goal in Opdivo NSCLC StudyKeytruda, also an anti-PD-1 therapy like Opdivo, is MRK’s blockbuster oncology drug. It is approved for several types of ...
JMP notes despite the incredible clinical and commercial success of Merck & Co. Inc’s (NYSE:MRK) Keytruda (pembrolizumab) and Bristol Myers Squibb & Co’s (NYSE:BMY) Opdivo (nivolumab ...
JMP notes despite the incredible clinical and commercial success of Merck & Co. Inc’s (NYSE:MRK) Keytruda (pembrolizumab) and Bristol Myers Squibb & Co’s (NYSE:BMY) Opdivo (nivolumab), ivonescimab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback